Navigation Links
First Patients in United States Receive Innovative Device to Treat Moderate Heart Failure
Date:4/21/2009

The Ohio State University Medical Center Implants Two Patients with Sunshine Heart's C-Pulse(TM) Heart Assist System Under FDA-Approved Clinical Trial

SYDNEY, and TUSTIN, Calif., April 21 /PRNewswire/ -- Sunshine Heart (ASX: SHC), a global medical device company focused on innovative heart assist technologies, announced today that The Ohio State University Medical Center in Columbus, Ohio has successfully completed the first two implants of the Company's C-Pulse(TM) heart assist system under a 20 person clinical trial approved by the U.S. Food and Drug Administration (FDA).

These C-Pulse systems were implanted by Dr. Benjamin Sun, Chief, Division of Cardiothoracic Surgery and Director, Cardiac Transplantation and Mechanical Support.

"It is an honor to have completed the first U.S. implants of the C-Pulse heart assist system," said Dr. Sun. "C-Pulse is highly innovative and implanted with a simple, low-risk minimally invasive surgical procedure. The device has the potential to offer a new therapy option for the treatment of moderate heart failure."

"We are excited that our clinical trial in the U.S. has started so successfully," said Dr. William Peters, Medical Director of Sunshine Heart and the inventor of C-Pulse. "We have demonstrated in prior clinical studies that the C-Pulse system increases blood flow to the body and to the heart muscle itself. We anticipate that C-Pulse will offer patients a significant improvement in quality of life." Dr. Peters went on to point out importantly that the device operates without coming into direct contact with the blood, so avoiding potential complications with systems that do contact blood. A feature of the design of the C-Pulse is that patients can safely disconnect from the device for short periods for their convenience."

"The completion of the initial C-Pulse implants in the U.S. is a major milestone for Sunshine Heart which is the only non-blood contacting heart assist device in clinical trials," said Don Rohrbaugh, the Company's CEO. "The start of our clinical trial brings us one step closer toward our goal to address the large and growing unmet clinical need for an alternative heart failure treatment to improve and sustain a patient's quality of life." Mr. Rohrbaugh noted, "C-Pulse is designed for Class III heart failure patients and these are defined as suffering continuing debilitating symptoms despite maximum drug therapy."

The 20 patient FDA-approved feasibility clinical trial is being undertaken at six U.S. medical institutions: Northwestern Memorial Hospital, The Ohio State Medical Center Jewish Hospital University (University of Louisville), Hershey Medical Center of the Pennsylvania State University, University of Florida School of Medicine and University of Alabama/ Birmingham Medical Center.

About Class III Heart Failure

Heart failure is a common condition in which the heart becomes unable to pump sufficient blood to meet the body's needs. Over five million people in the United States have heart failure and it results in over 300,000 deaths each year. Heart failure is a progressive condition and typically results from damage to the heart muscle arising from a heart attack or virus.

Cardiologists use a classification system to define the four classes of heart failure; each class is determined by rating a patient's symptoms to everyday activities and quality of life. Over 1.4 million US heart failure patients are in the Class III or moderate heart failure category which is defined by the limitation of physical activity. These patients are comfortable at rest, but levels of activity regarded as less than ordinary cause fatigue, palpitation, and/or shortness of breath. The most common treatments for Class III heart failure are drugs, lifestyle adjustments, family education, device therapy (i.e. heart failure pacemaker with or without a defibrillator), or surgery. A major medical treatment challenge is that the medical regimen and CRT options often stop alleviating symptoms over time, hence the need for C-Pulse heart assist.

About Sunshine Heart

Sunshine Heart (ASX: SHC) (www.sunshineheart.com) is a global medical device company, committed to the commercialization of C-Pulse(TM) an implantable, non-blood contacting, heart assist therapy for the treatment of people with moderate heart failure. C-Pulse reduces the symptoms of heart failure through the use of counterpulsation technology which enables an increase in cardiac output, an increase in coronary blood flow and reduction in the heart's pumping workload. The Company has received approval from the U.S. Food and Drug Administration (FDA) to conduct a 20 person U.S. feasibility clinical trial with C-Pulse and patient enrolment and implants have commenced. Sunshine Heart listed on the ASX in September 2004 has a presence in Australia, New Zealand and the United States of America.

For further information, please visit www.sunshineheart.com or contact:

    Don Rohrbaugh
    Chief Executive Officer
    +1 714 259 0732
    don.rohrbaugh@sunshineheart.com

    Investors/Media:
    The Ruth Group
    R.J. Pellegrino/Scott Lerman
    646-536-7009/7013
    rpellegrino@theruthgroup.com
    slerman@theruthgroup.com

This press release may contain forward-looking statements that are based on current management expectations. These statements may differ materially from actual future events or results due to certain risks and uncertainties from time to time in the Company's filings with the Australian Securities Exchange.


'/>"/>
SOURCE Sunshine Heart
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. The ASDS Introduces the First At-Home Skin Cancer Exam Kit
2. Quest Diagnostics Reports Strong Earnings Growth In First Quarter 2009
3. Worlds First Disposable Wireless RFID Sensor Detects Radiation Threats in Shipping Containers Using Modified Cell Phone Technology
4. Schering-Plough Reports Financial Results for 2009 First Quarter
5. Stereotaxis Announces First Quarter 2009 Earnings Release Date and Conference Call
6. Boston Scientific Announces Results For First Quarter Ended March 31, 2009
7. Young Innovations, Inc. Provides First Quarter Conference Call Details
8. Insulet Corporation to Report First Quarter 2009 Financial Results on Thursday, May 7, 2009
9. Lincare Holdings Inc. Announces First Quarter 2009 Financial Results
10. Amgen Announces Webcast of 2009 First Quarter Financial Results
11. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET April 27, 2009 to Discuss First Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2017)... CANADA (PRWEB) , ... July 22, 2017 , ... ... offer patients with irreparable rotator cuff repairs the opportunity to return to sports ... the American Orthopaedic Society for Sports Medicine’s Annual Meeting in Toronto, ...
(Date:7/21/2017)... ... ... The Ellis Agency, an eastern Georgie provider of insurance management and financial ... event with the goal of bringing in support for epilepsy patients in the greater ... recently launched a charity campaign of her own by donating her birthday to the ...
(Date:7/21/2017)... Long Grove, Ill. (PRWEB) , ... July 21, 2017 , ... ... Air & Fabric Liquid eco-friendly odor-control solution for colleges and universities at the ... to safely and effectively eliminate severe cannabis and tobacco smoke odors without the use ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... The Margarian ... falsely advertising the contents of its ginger ale for allegedly containing no ginger. Dr. ... Dr. Pepper Snapple Group, Inc., plaintiff Gegham Margaryan alleges Canada Dry Ginger Ale claims ...
(Date:7/21/2017)... ... July 21, 2017 , ... “Kids aren't born knowing ... tie their shoes,” says Suzanne Tucker, Founder of St. Louis-based positive education company Generation ... launches on Kickstarter on Monday, July 21st. , The kit uses colorful, engaging ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... July 13, 2017  New York City-based market research firm ... should be aware of.  From new products to new costs, ... in a recently completed study, Potential Pipeline Disruptors . ... 1.  Age-Driven Growth - True Impact ... aware of the impact the growing population and, to a ...
(Date:7/11/2017)... , July 11, 2017  The global market ... revenues of approximately $394.1 million in 2016.  Although in ... of solid growth, in particular as a result of ... practice, and the recent introduction of a significant number ... for less-invasive testing of tumor biomarkers to guide treatment ...
(Date:7/10/2017)... Md. , July 10, 2017 The ... non-animal test methods, is the recipient of a VITROCELL® ... the PETA International Science Consortium. The device, which is ... used to expose human lung cells to airborne test ... IIVS will use the VITROCELL® system for testing combustible ...
Breaking Medicine Technology: